Pulmonary embolism can occur even while you are taking blood thinners, and it happens more often than most people expect. These events, sometimes called “breakthrough” clots, have been documented in medical research going back decades, and they remain one of the more unsettling realities of anticoagulant therapy. The reasons range from missed doses and drug interactions to underlying conditions that make clotting unusually aggressive, and understanding those reasons matters both for peace of mind and for knowing when to push for a closer look at your treatment plan.
How Common Are Breakthrough Clots?
The numbers depend partly on why you started blood thinners in the first place. A pooled analysis of studies found that among patients who initially presented with deep vein thrombosis, the rate of fatal pulmonary embolism during anticoagulant therapy was about 0.4%. Among patients whose original event was a pulmonary embolism, that rate climbed to roughly 1.5%.1PubMed. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism Those figures only capture fatal clots. Non-fatal recurrences are more common, and the case-fatality rate for any recurrent clot event during therapy ranged from about 9% for patients whose initial event was a DVT up to roughly 26% for those who originally had a PE.1PubMed. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism In other words, blood thinners dramatically reduce the risk of another clot, but they do not eliminate it entirely.
These are population-level averages. Your personal risk depends on a web of factors, and several of them are modifiable or at least identifiable. That is worth knowing, because when a breakthrough clot does happen, the response often hinges on figuring out which of those factors failed.
Missed Doses and Adherence Problems
The most straightforward reason a blood thinner can fail is that not enough of it is in your system. With the newer direct oral anticoagulants (often shortened to DOACs), which include drugs like apixaban, rivaroxaban, dabigatran, and edoxaban, a single missed or delayed dose can create a window of reduced protection. These medications wash out of your body faster than the older drug warfarin, so gaps in coverage happen quickly. Research confirms that poor adherence to DOACs is linked to a higher risk of clotting events, bleeding events, and even death from all causes.2PubMed Central. Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing
What makes adherence tricky is that DOACs don’t require the routine blood monitoring that warfarin does. With warfarin, you get regular INR checks, and if your level drifts low, your doctor catches it. With a DOAC, there is no standard blood test telling you whether your drug levels are adequate on any given day. That freedom from regular lab visits is a major convenience, but it also means missed doses or inconsistent timing can go unnoticed until a clot appears.
Kidney function adds another layer. All four major DOACs are cleared partly through the kidneys, and people with reduced kidney function clear the drugs more slowly. For someone with moderately impaired kidney function, DOAC clearance may drop by 14% to 32% compared to someone with normal kidneys, depending on the specific drug.2PubMed Central. Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing Doses are often adjusted for this, but if kidney function changes over time and nobody rechecks, you can end up on the wrong dose without realizing it.
Drug Interactions That Weaken Anticoagulants
Blood thinners share metabolic pathways with many other medications, and some of those interactions can quietly reduce how well an anticoagulant works. DOACs are processed in the body through systems involving a protein called P-glycoprotein and, for some drugs, an enzyme family called CYP3A4. Medications that strongly activate these systems can speed up the removal of the blood thinner from your body, lowering its effective concentration. Strong inducers of CYP3A4 or P-glycoprotein should be avoided in patients on any DOAC unless specifically proven safe, and the combination of strong inhibitors of both pathways should be avoided with apixaban and rivaroxaban.3PubMed Central. Drug Interactions Affecting Oral Anticoagulant Use
Common culprits include certain antiseizure drugs, some antibiotics, the tuberculosis drug rifampin, and the herbal supplement St. John’s wort. These can ramp up drug metabolism enough to leave you functionally under-anticoagulated. The tricky part is that these interactions don’t always produce obvious symptoms. You feel fine, your medication looks the same, but the effective dose circulating in your blood has quietly dropped.
Warfarin is subject to a different but equally complicated set of interactions. Because it’s metabolized by the CYP2C9 enzyme and works by blocking vitamin K recycling, anything that affects either pathway can shift your INR. Foods rich in vitamin K (leafy greens, for example), alcohol, and dozens of commonly prescribed medications can push your INR up or down. This is why warfarin patients need regular monitoring, but even with monitoring, there are periods where the INR drifts outside the therapeutic window.
When Genetics Play a Role
For warfarin specifically, how your body handles the drug is partly written into your DNA. Two genes have an outsized influence: CYP2C9, which encodes the enzyme that metabolizes warfarin, and VKORC1, which encodes the protein that warfarin targets. Variants in CYP2C9 can decrease the enzyme’s activity, meaning warfarin lingers longer and a lower dose is needed. VKORC1 variants have an even larger effect, roughly threefold greater than CYP2C9 in explaining why two people on the same dose can have very different drug levels.4Biochemia Medica. The pharmacogenetics of warfarin in clinical practice Carrying variants in both genes simultaneously is linked to a risk of severe over-anticoagulation, while having neither variant might mean the standard dose isn’t quite enough.
These genetic variations are remarkably common. In one study of the Israeli population, approximately 84% to 95% of people across several ethnic subgroups carried at least one variant allele known to affect warfarin sensitivity or resistance.5PubMed. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population Pharmacogenomic testing before starting warfarin is available and can help dial in the right dose faster, but it is not yet standard practice everywhere. When it’s skipped, some patients spend weeks on a dose that’s too low to protect them adequately.
Cancer and the Clotting Arms Race
Cancer deserves its own discussion because it fundamentally changes the relationship between blood thinners and clotting. Tumors can actively promote clot formation through several mechanisms, including releasing substances that activate the clotting cascade, compressing veins, and triggering inflammatory responses. Patients with cancer face a higher risk of both recurrent clots and major bleeding, which puts their doctors in an unenviable balancing act.6PubMed Central. Pulmonary embolism in cancer patients. Effectiveness of vitamin K antagonists and direct oral anticoagulants in long-term therapy
Breakthrough clots in cancer patients are common enough that specific protocols exist for managing them. In one study of 55 cancer patients who had a recurrent clot despite already being on anticoagulation, 89% were on low-molecular-weight heparin (an injectable blood thinner considered the traditional standard for cancer-associated clots) at the time of recurrence. The median time from initial clot to breakthrough event was about 2.3 months. The management strategy was to increase the heparin dose, which kept most patients from having another recurrence during follow-up, though about 7% clotted again and roughly 5.5% had a major bleed after the dose was raised.7PubMed. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis
This illustrates the core challenge with cancer-associated clots: standard doses of even the right drug are sometimes not enough, because the cancer itself is continuously stoking the clotting machinery. Higher doses carry more bleeding risk, and the “right” balance shifts as the cancer progresses or responds to treatment.
Autoimmune Conditions That Drive Clotting
Antiphospholipid syndrome is an autoimmune disorder where the body produces antibodies that promote abnormal clotting. It is one of the most recognized causes of treatment-resistant blood clots, and managing it with anticoagulants is notoriously difficult. The antibodies themselves don’t guarantee a clot will form; researchers believe a “second hit,” such as surgery, pregnancy, or infection, is often needed to trigger an event. But once clotting starts, it tends to be aggressive and recurrent.8PubMed Central. Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
The ideal intensity of anticoagulation for antiphospholipid syndrome patients remains an open question. Some clinicians target a higher INR with warfarin; others have tried DOACs, but clinical trials have generally not favored switching away from warfarin for these patients, particularly those who test positive for multiple antibody types. If you’ve been diagnosed with antiphospholipid syndrome and experience a breakthrough clot, the treatment adjustment is often more complex than simply increasing the dose.
Absorption Problems After Bariatric Surgery
Bariatric surgery reshapes the digestive tract, and that can have real consequences for how oral medications are absorbed. Surgery may alter the acidity of the stomach, reduce the surface area available for absorption, or speed up transit through the gut. For blood thinners taken by mouth, this matters because the drug may not reach therapeutic levels even when taken as prescribed.9PubMed Central. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance
Research on this is still limited, but early findings are striking. In a study comparing post-bariatric patients to controls, five of the bariatric patients had peak drug levels below the expected range, compared to none of the control subjects. The effect was especially pronounced with rivaroxaban: all four patients who had undergone sleeve gastrectomy had rivaroxaban levels below the expected range, and overall peak rivaroxaban levels were significantly lower in the bariatric group.10PubMed. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels Apixaban and dabigatran fared somewhat better in that small sample, but the overall message is cautious: if you’ve had bariatric surgery and need full-dose anticoagulation, warfarin with regular INR monitoring may be the safer bet until more data on DOACs in this population exist.
Anatomical Quirks That Blood Thinners Cannot Fix
Sometimes the problem isn’t the drug or the disease but the physical plumbing. May-Thurner syndrome is a condition where the left iliac vein (a major vessel in the pelvis) is compressed by the overlying right iliac artery. This compression slows blood flow and creates a setup for clots in the left leg, which can then travel to the lungs. Even after treatment with a vein stent and anticoagulation, the recurrence rate is not trivial. In a systematic review, stent thrombosis or occlusion occurred in roughly 10% to 20% of patients regardless of the type of anticoagulation used, with an overall rate of about 13% at 12 months.11PubMed Central. May‐Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement In some cases within that review, stent failure was linked to stopping warfarin or not taking it consistently.
May-Thurner is just one example. Other anatomical issues, such as congenital abnormalities of the vena cava or significant pelvic masses compressing veins, can create mechanical conditions that blood thinners alone cannot fully overcome. The drugs prevent new clot formation, but they don’t fix sluggish blood flow caused by physical compression.
What Doctors Do When a Clot Breaks Through
When a clot happens despite anticoagulation, the first clinical priority is confirming the diagnosis and then trying to understand why the treatment failed. The response depends on the suspected cause. If missed doses or a drug interaction is identified, restoring adequate drug levels may be enough. If the patient is on a DOAC, switching to a different anticoagulant or adjusting the dose is common. If the patient is on warfarin and the INR was subtherapeutic, the fix might be as straightforward as adjusting the dose and monitoring more frequently.
The uncomfortable truth, though, is that evidence-based guidance for managing breakthrough clots is thin. As one review in a leading hematology journal put it, while the mechanisms behind treatment failure are usually well understood, the management of further anticoagulation after a breakthrough event relies on minimal or no clinical trial evidence.12PubMed. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy In practice, doctors often escalate treatment, perhaps switching from a DOAC to low-molecular-weight heparin, increasing the dose of an injectable, or adding a mechanical intervention.
One such mechanical intervention is an inferior vena cava (IVC) filter, a small device placed inside the large vein leading to the heart to catch clots before they reach the lungs. IVC filters are sometimes used when anticoagulation isn’t working or can’t be given at all. However, the evidence for their effectiveness is mixed. A study comparing outcomes in patients who received IVC filters to those managed with anticoagulation alone found no significant differences in outcomes once the groups were matched for overall health severity.13PubMed Central. Effectiveness of Inferior Vena Cava Filters without Anticoagulation Therapy for Prophylaxis of Recurrent Pulmonary Embolism IVC filters also come with their own risks, including migration and the potential for the filter itself to cause clots, so they’re generally considered a backup option rather than a first-line solution.
The Challenge of Monitoring Newer Blood Thinners
One reason breakthrough events can catch people off guard is that there’s currently no widely used, routine blood test that tells you whether your DOAC is at the right level. Drug-specific laboratory assays do exist and can measure the amount of drug in your blood, but they are not available everywhere, and there are no established therapeutic ranges that clearly separate “protected” from “unprotected.”14PubMed Central. DOACs: role of anti-Xa and drug level monitoring This is a significant gap in care compared to warfarin, where the INR gives a clear, standardized measure of anticoagulation intensity.
For most patients on DOACs, the assumption is that taking the prescribed dose on schedule produces adequate drug levels. That assumption works well for the average person with normal kidney function, no major drug interactions, and consistent absorption. It works less well for patients who fall outside those parameters. Until drug-level monitoring for DOACs becomes routine and standardized, clinicians are often flying somewhat blind when it comes to confirming that a patient is actually achieving the intended level of anticoagulation.
Long-Term Consequences of Clots That Slip Through
A breakthrough PE is not just a repeat of the original event; it can contribute to lasting damage in the lungs. One concerning long-term complication is chronic thromboembolic pulmonary hypertension (CTEPH), a condition where unresolved clot material in the pulmonary arteries raises pressure in those vessels permanently. In a study that followed PE survivors for six months, some form of elevated pulmonary pressure was found in about 40% of patients, though only about 7% had symptoms at that point.15PubMed Central. The Incidence and Related Risk Factors of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism The gap between the number of patients with detectable pressure elevation and those with symptoms suggests that CTEPH can silently develop and may not become apparent until the lungs have absorbed significant damage.
Each additional PE raises the cumulative burden on the pulmonary vasculature. This is part of why breakthrough clots are taken so seriously: it’s not just the acute danger of a clot blocking blood flow, but the incremental damage to a system that doesn’t regenerate easily. If you’ve had a PE on blood thinners and you notice worsening shortness of breath, fatigue with exertion, or an exercise tolerance that seems to be declining over months, it’s worth asking your doctor about screening for CTEPH.
The Emotional Weight of a Breakthrough Event
Something that often gets overlooked in clinical discussions is the psychological fallout. People who’ve had a PE frequently describe ongoing anxiety, hypervigilance about physical symptoms, and a lasting sense that their body has betrayed them. Research using mixed-methods approaches has documented that the psychological impact of PE extends well beyond the acute event.16PubMed Central. The psychological impact of pulmonary embolism: A mixed‐methods study When a clot occurs while you’re already on the medication designed to prevent it, that emotional burden compounds. Patients describe a loss of trust in their treatment and an amplified fear that every twinge or shortness of breath might signal another event.
This psychological dimension matters practically, too. Anxiety about recurrence can lead to both over-monitoring (calling 911 for every chest sensation) and paradoxically to avoidance (skipping exercise or travel out of fear). If you’ve experienced a breakthrough clot, acknowledging the emotional component and seeking support, whether through a structured program, a therapist familiar with chronic illness, or a patient support community, is a legitimate part of recovery and not a sign of weakness.
When to Speak Up
If you are on blood thinners and experience sudden shortness of breath, chest pain that worsens with breathing, unexplained rapid heart rate, or coughing up blood, those symptoms warrant immediate medical evaluation regardless of your anticoagulation status. The presence of a blood thinner in your system does not rule out a PE, and assuming you’re “covered” is one of the more dangerous misconceptions patients carry. Emergency physicians know this, but patients sometimes delay seeking care because they believe the medication makes another clot impossible.
Beyond emergencies, there are conversations worth having with your prescribing doctor. If you’ve had bariatric surgery, if your kidney function has changed, if you’ve started a new medication, or if you’ve been inconsistent with your doses, all of these are reasons to revisit whether your current regimen is doing what it’s supposed to. The absence of routine drug-level monitoring for DOACs makes this kind of proactive communication even more important. You are, in a sense, part of the monitoring system.